Regeneron Pharma (REGN) Repors Prelim. Q4 U.S. EYLEA Sales of ~$400M; Issues Update

On January 14, 2014, at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, California, Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN), is providing a corporate update. Dr. Schleifer’s presentation includes information regarding the Company’s preliminary U.S. net sales of EYLEA® (aflibercept) Injection for the fourth quarter and full year 2013. Key points: -- U.S. EYLEA net sales in 2013 at about $1.4 billion, Q4 at about $400 million -- U.S. EYLEA distributor inventory increased to slightly over two weeks; inventory historically at 1 to 2 weeks -- U.S. EYLEA commercial terms tightened in January 2014 -- EYLEA PDUFA date of August 18, 2014 -- U.S. EYLEA BRVO filing expected in Q114 -- Sees FY14 non-GAAP SG&A at $330 to $380 million -- FY14 non-GAAP reimbursed R&D at $425 to $475 million -- FY14 CapEx at $350 to $425 million

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• American Express (AXP) down despite beating Q1 estimates on top and bottom lines
• Snail (SNAL) Announces Resignation of Chief Strategy Officer and Chairman
• ContextLogic (WISH) Receives Stockholder Approval of Transaction with Qoo10